FDA Approves Single Dose Option for Iron Replacement Therapy Injectafer
For patients weighing at least 50kg, Injectafer may be administered as a single dose option of 15mg/kg body weight up to a maximum of 1000mg intravenously.
Chronic Kidney Disease
Dapagliflozin Reduces Risk for Kidney Events in IgA Nephropathy
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
Farxiga Approved for Patients With CKD at Risk of Progression
The approval was based on data from the DAPA-CKD trial, which compared dapagliflozin, an SGLT2 inhibitor, to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
DOACs Appear Safer Than Warfarin Across Chronic Kidney Disease Stages
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
Bardoxolone Under Review for CKD Caused by Alport Syndrome
The NDA submission includes data from the phase 3 CARDINAL trial that evaluated the efficacy and safety of bardoxolone in 157 patients with CKD caused by Alport syndrome.
Tenapanor May Improve Phosphate Normalization in the Dialysis Population
Tenapanor inhibits the sodium hydrogen exchanger 3 (NHE3), reducing paracellular uptake of phosphate in the intestine.
Sodium Bicarbonate May Mitigate Calcium Phosphate Stone Risk in CKD
Oral sodium bicarbonate therapy given to patients with chronic kidney disease increases urinary pH but also increases urinary citrate levels, which may mitigate the risk for calcium phosphate stone formation.
Study: Roxadustat Effectively Treats Anemia Across CKD Stages
Roxadustat reduced the need for rescue therapy among patients with any stage of chronic kidney disease.
Why Racial and Ethnic Disparities Exist in Kidney Disease Care
Lack of timely referrals to nephrologists contribute to racial and ethnic disparities in kidney disease care.
Vadadustat NDA Submitted for Anemia Due to Chronic Kidney Disease
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
